1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation
| Autor: | Puzanov, I., Havenith, K., Boni, J., Cruz, H.G., Anderson, K., Kopotsha, T., Le Bruchec, Y., Bendell, J.C., Kummar, S., Papadopoulos, K.P., LoRusso, P., Wuerthner, J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S710-S711 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|